Participated · Series A · Aug 2026

KaliVir develops next-generation oncolytic immunotherapies using its proprietary Vaccinia Enhanced Template (VET) platform to integrate multiple genetic modifications into viral backbones for systemic delivery and targeted expression of therapeutic transgenes within tumors. Its lead candidate, VET3-TGI, is being evaluated as both monotherapy and in combination with atezolizumab in the STEALTH-001 Phase 1/1b trial for patients with advanced solid tumors. The company plans to use the newly raised funds to support ongoing clinical development and patient enrollment in STEALTH-001 and for general corporate purposes. KaliVir is led by CEO Helena Chaye, PhD, JD, and is based in Pittsburgh, PA. Financially, the company has now raised a total of $25M following the $14M Series A extension.

Participated · Equity · Jun 2026

Enventric develops vascular medical devices for cerebral infarction treatment, with approved products including the EvoGlide distal access catheter and the ULTRIVA stent retriever. The company reported cumulative revenue of about 6 billion won over the past four years and a compound annual growth rate of 52.9% over that period. Enventric is accelerating R&D and expanding manufacturing capacity following recent regulatory approvals. It is pursuing global market entry and has begun formal IPO preparations on KOSDAQ, appointing Kiwoom Securities as its underwriter. The recent 34.5 billion won pre-IPO equity raise broadens its institutional investor base and includes follow-on participation from several existing investors. Management has stated the capital will be used to bolster R&D, scale manufacturing, and support the company’s listing and international expansion efforts.

Participated · Series B · Jun 2026

Promedius develops Osteo Signal, an AI-based screening solution that analyzes routine chest radiographs to assess osteoporosis risk in about three seconds and identify at-risk patient groups without additional tests. Osteo Signal was designated an innovative medical device in 2024 and received approval from the Korean Ministry of Food and Drug Safety in 2025; the company has also secured regulatory approvals in Vietnam and Indonesia and is seeking FDA and CE/MDR clearances by the end of the year. Promedius has built partnerships with global medical device companies such as Siemens Healthineers and secured strategic investors including Daewoong Pharmaceutical and Naver to support commercial rollout. The company aims to commercialize nationally and expand internationally while broadening its platform to address healthy aging conditions like sarcopenia, metabolic and cardiovascular diseases. Its total funding now exceeds 35 billion won following the recent Series B raise of 21.5 billion won.

Participated · Series C · Apr 2026

Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.

Participated · Series B · Jul 2025

Illimis Therapeutics develops therapies for central nervous system and immune disorders using its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. The company's lead program, ILM01 for Alzheimer's Disease, is entering preclinical development in the second half of 2025 with an IND targeted by the end of 2027. Proceeds from the recent financing will accelerate GAIA-based Alzheimer's programs, expand target indications into various immune disorders, and broaden its pipeline toward potential blockbuster candidates. Illimis is pursuing early-stage co-development with global pharmaceutical companies and research institutions and has established collaborations including Eli Lilly's Catalyze360-ExploR&D, participation in BMS Innovation Square Challenge, and membership in JLABS Singapore. A Scientific Advisory Board that includes Dr. Greg Lemke and Dr. Morgan Sheng provides strategic guidance across R&D, candidate discovery, and clinical trial design. The company was selected for the '2025 Global Joint Research to Defeat Dementia' and secured KRW 2.2 million ($1.6 million) in funding over three years to support international Alzheimer's research efforts.